From: Medicines availability for non-communicable diseases: the case for standardized monitoring
Medicine | Mean availability (%) of medicine | ||||
---|---|---|---|---|---|
Peck et al. | WHO/HAI | SARA | |||
All facilities# | Diabetes services | Cardiovascular disease services | |||
N = 24 | N = 107 | N = 1297 | N = 248 | N = 316 | |
Diabetes | |||||
Glibenclamide | 47* | 19* | 52 | ||
Metformin | 33 | 46† | 57 | 39 | |
Insulin | 17; 8; 8‡ | 34 | |||
Hypertension | |||||
Captopril 25 mg | 48 | 13 | |||
Captopril or lisinopril | 25 | ||||
ACE inhibitors | 24 | ||||
Nifedipine | 33 | 57§ | |||
Calcium channel blockers | 29 | ||||
Atenolol 50 mg | 48 | 15 | |||
Atenolol or propranolol | 50 | ||||
Beta-blockers | 41 | ||||
Hydrochlorothiazide or bendrofluazide | 33 | 31¥ |